Archive

Tag: ICH

Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?

Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban and apixaban are associated with ICH at rates that range from 0.1 to 4% (Agnelli …

Read More
Hematology and OncologyNeurologyTrauma

Factor Xa Inhibitor Related ICH & PCCs

Background: Factor Xa inhibitors have gained more use over the past several years due to the ease of administration and easier monitoring. However, bleeding, namely intracranial hemorrhage (ICH) is still a risk and the lack of a proven antidote is …

Read More
Hematology and Oncology

CRASH-3: TXA for ICH?

Background: Evidence from the CRASH-2 trial showed an absolute reduction in mortality of 1.5% (NNT = 67) in patients with extracranial bleeding treated with tranexamic acid  (TXA) within 3 hours of injury. However, CRASH-2 did not answer the question of …

Read More
Trauma

TICH-2: TXA for Spontaneous ICH?

Background: Spontaneous, non-traumatic intracerebral hemorrhage, is one of the only stroke subtypes without a proven treatment. It is not as common as ischemic stroke, representing up to 20% of all strokes, but it accounts for almost half of all stroke deaths worldwide.  …

Read More
Neurology

The PATCH Trial: Hold the Platelets in Spontaneous Intracerebral Hemorrhage?

Background: Hemorrhagic stroke accounts for 11 – 22% of strokes, half of all stroke deaths, and a significant amount of disability in many of the remaining survivors. Spontaneous, non-traumatic, intracerebral hemorrhage (ICH) accounts for 2/3 of hemorrhagic strokes; estimated at …

Read More
Neurology

Sponsored

0